Dr. Diana Hausman, M.D.
Dr. Hausman has served on our Board of Directors since January 2022. Dr. Hausman currently serves as the Chief Medical Officer of Zentalis Pharmaceuticals, Inc.(“Zentalis”), a position she has held since January 2024. Previously, Dr. Hausman served as the Chief Medical Officer of Link Immunotherapeutics from March 2022 to October 2023, and from June 2021 to March 2022 served as the Chief Medical Officer of Lengo Therapeutics (“Lengo”), a wholly-owned subsidiary of Blueprint Medicines Corporation. Prior to Lengo, Dr. Hausman served as Chief Medical Officer for Zymeworks Inc. from June 2016 to May 2021, and as Chief Medical Officer for Oncothyreon Inc. from 2009 to 2016. She also held positions of increasing responsibility at ZymoGenetics Inc., Berlex Inc., and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. From May 2023 to January 2024, Dr. Hausman served as a member of the board of directors of Zentalis. Dr. Hausman received her A.B. in biology from Princeton University, her M.D. from the University of Pennsylvania, and her internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle.